|Ms. Emma N. Walmsley||CEO & Director||3,29M||1,6M||1970|
|Mr. Iain James Mackay||CFO & Exec. Director||2,36M||N/A||1962|
|Dr. Hal V. Barron||Chief Scientific Officer, Pres of R&D and Director||6,34M||N/A||1963|
|Ms. Karenann K. Terrell||Chief Digital & Technology Officer||N/A||N/A||1961|
|Ms. Sarah Elton-Farr||Head of Investor Relations||N/A||N/A||N/A|
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; and Sanofi SA. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline plcs ISS Governance QualityScore, Stand 7. Dezember 2019, lautet 6. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 1, Kompensation: 9.